These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7592026)

  • 1. Rifampicin inactivation by Bacillus species.
    Dabbs ER; Yazawa K; Tanaka Y; Mikami Y; Miyaji M; Andersen SJ; Morisaki N; Iwasaki S; Shida O; Takagi H
    J Antibiot (Tokyo); 1995 Aug; 48(8):815-9. PubMed ID: 7592026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different rifampicin inactivation mechanisms in Nocardia and related taxa.
    Tanaka Y; Yazawa K; Dabbs ER; Nishikawa K; Komaki H; Mikami Y; Miyaji M; Morisaki N; Iwasaki S
    Microbiol Immunol; 1996; 40(1):1-4. PubMed ID: 8871521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interspecific transformation of rifampicin resistance in the genus Bacillus.
    Harford N; Mergeay M
    Mol Gen Genet; 1973 Jan; 120(2):151-5. PubMed ID: 4631265
    [No Abstract]   [Full Text] [Related]  

  • 4. Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene.
    Dabbs ER; Quan S
    FEMS Microbiol Lett; 2000 Jan; 182(1):105-9. PubMed ID: 10612740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibacterial activity of rifampicin against the causative agents of suppurative, septic diseases].
    Samoĭlova LN; Fomina IP; Bodunkova LE
    Antibiotiki; 1977 Jan; 22(1):46-50. PubMed ID: 402885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of a Rif-R population of Bacillus anthracis].
    Pomerantsev AP; Sukovatova LV; Marinin LI
    Antibiot Khimioter; 1993; 38(8-9):34-8. PubMed ID: 8037574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning of nocardioform DNA conferring the ability to inactivate rifampicin.
    Andersen SJ; Dabbs ER
    FEMS Microbiol Lett; 1991 Apr; 63(2-3):247-50. PubMed ID: 2060762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of DNA-repair-deficient strains of Escherichia coli to rifampicin killing.
    Chao L
    Mutat Res; 1986 Jan; 173(1):25-9. PubMed ID: 3510379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum.
    Yazawa K; Mikami Y; Maeda A; Morisaki N; Iwasaki S
    J Antimicrob Chemother; 1994 Jun; 33(6):1127-35. PubMed ID: 7928806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green synthesis of rifampicin-loaded copper nanoparticles with enhanced antimicrobial activity.
    Woźniak-Budych MJ; Przysiecka Ł; Langer K; Peplińska B; Jarek M; Wiesner M; Nowaczyk G; Jurga S
    J Mater Sci Mater Med; 2017 Mar; 28(3):42. PubMed ID: 28150115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bacteriological studies on rifampicin, a new antibiotic. 2. Antimicrobial activity of desacetyl-rifampicin].
    Nakazawa S; Ishiyama M; Oshima Y; Osada Y
    Jpn J Antibiot; 1970 Jun; 23(3):240-1. PubMed ID: 4920336
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens.
    Chandrasekaran S; Lalithakumari D
    J Med Microbiol; 1998 Mar; 47(3):197-200. PubMed ID: 9511824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of rifampicin on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.
    Xiong YQ; Caillon J; Drugeon H; Potel G; Baron D
    J Antimicrob Chemother; 1996 May; 37(5):993-8. PubMed ID: 8737149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro sensitivity of Staphylococcus and gram negative bacteria to rifampicin].
    Ales Reinlein AM; Fernández Puentes MC; Torres Cid A
    Rev Clin Esp; 1973 Jul; 130(2):99-102. PubMed ID: 4742347
    [No Abstract]   [Full Text] [Related]  

  • 15. [Isolation and characteristics of rifampicin-resistant mutants of Streptomyces erythraeus strain].
    Nastasiak IN; Fedorenko VA; Kirichenko NV; Danilenko VN
    Antibiot Khimioter; 1990 Dec; 35(12):11-3. PubMed ID: 2078070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus.
    Røder BL; Gutschik E
    J Antimicrob Chemother; 1989 Mar; 23(3):347-52. PubMed ID: 2732119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacteriological studies on rifampicin, a new antibiotic].
    Nakazawa S; Ishiyama M; Otsuki M; Kakita K; Kimura K
    Jpn J Antibiot; 1969 Aug; 22(4):276-86. PubMed ID: 4901099
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus.
    Eng RH; Smith SM; Buccini FJ; Cherubin CE
    J Antimicrob Chemother; 1985 Feb; 15(2):201-7. PubMed ID: 3845078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethoprim and rifampicin: in vitro activities separately and in combination.
    Kerry DW; Hamilton-Miller JM; Brumfitt W
    J Antimicrob Chemother; 1975 Dec; 1(4):417-27. PubMed ID: 1206027
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis.
    Siddiqi SH; Aziz A; Reggiardo Z; Middlebrook G
    J Clin Pathol; 1981 Aug; 34(8):927-9. PubMed ID: 6792243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.